8-K: Dare Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Dare Bioscience announced its 2023 financial results and provided a company update, highlighting progress with its late-stage candidates and on-market product, XACIATO.

Summary

• Dare Bioscience reported its financial results for the year ended December 31, 2023, and provided a company update.
• The company highlighted the U.S. launch of XACIATO, completion of the Sildenafil Cream Phase 2b study, and commencement of the Ovaprene Phase 3 study.
• Dare Bioscience received a $1.8 million milestone payment from Organon for the first shipment of XACIATO.
• The company's total revenue for 2023 was approximately $2.8 million, including payments related to XACIATO.
• Dare Bioscience reported a net loss of approximately $30.1 million for 2023.
• General and administrative expenses for 2023 were approximately $12.1 million, with a projected reduction to approximately $10.0 million in 2024.
• Research and development expenses were approximately $21.5 million in 2023, expected to be considerably less in 2024 due to the completion of several studies.
• The company had $10.5 million in cash and cash equivalents at the end of 2023.
• Dare Bioscience is actively recruiting for the Ovaprene Phase 3 study across 17 sites in the United States.
• The company is awaiting additional FDA feedback on the Phase 3 design for Sildenafil Cream, expected in the second quarter of 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in clinical trials and product launches, but also acknowledges financial losses and the need for further funding. The sentiment is cautiously optimistic.

Positives

• XACIATO is now available by prescription in the U.S., providing a non-dilutive revenue source for Dare Bioscience.
• The company received a $1.8 million milestone payment for the first shipment of XACIATO.
• The Ovaprene Phase 3 study has commenced, representing a significant step forward for a potential first-in-category product.
• Positive data was achieved for Sildenafil Cream in the Phase 2b study, with a successful end-of-Phase 2 meeting with the FDA.
• The company has a diverse portfolio of product candidates in various stages of development.
• Dare Bioscience secured $4.7 million in non-dilutive grant funding and $19 million in financing during 2023.
• The company expects a reduction in G&A expenses in 2024.

Negatives

• Dare Bioscience reported a net loss of approximately $30.1 million for 2023.
• The company's cash and cash equivalents were $10.5 million at the end of 2023.
• The company is dependent on third parties for clinical trials and manufacturing.
• There is a risk that the FDA may not agree with the company's interpretation of clinical data.
• The company is subject to risks related to competition, intellectual property, and regulatory changes.

Risks

• Dare Bioscience's ability to raise additional capital is crucial for advancing its product candidates and continuing as a going concern.
• There are risks associated with the development, regulatory approval, and commercialization of product candidates.
• The company faces risks related to clinical trial failures, delays, and safety concerns.
• Dependence on third parties for clinical trials and manufacturing poses a risk to the company's operations.
• The company is subject to risks related to competition, intellectual property, and regulatory changes.
• Macroeconomic conditions, geopolitical events, and public health emergencies could impact the company's operations and financial results.

Future Outlook

Dare Bioscience anticipates meaningful milestones in 2024 across multiple programs, including updates on the Ovaprene Phase 3 study, FDA feedback on Sildenafil Cream, and continued commercialization of XACIATO. The company also plans to evaluate a wide range of financing opportunities to fund its portfolio.

Management Comments

• We are pleased with the incredible progress we made in 2023 with our late-stage candidates and on-market product, including the U.S. launch of XACIATO, Sildenafil Cream Phase 2b study completion and Ovaprene Phase 3 study commencement, which put us on track for meaningful milestones in 2024 across multiple programs.
• I had the pleasure of attending in person both the ARPA-H Sprint for Womens Health announcement event in Boston in February and the White House reception in March in honor of Womens History Month where President Biden signed an executive order dedicated to advancing womens health research, and it is encouraging to see further, comprehensive action aimed at increasing investments in womens health.
• We look forward to continuing to execute on our mission to accelerate development of and bring to market innovative treatments that women want and need, and to evaluate a wide range of financing opportunities to fund our robust portfolio.

Industry Context

The announcement comes amid increased attention and investment in women's health, as highlighted by the ARPA-H Sprint for Women's Health and the White House reception in honor of Women's History Month. This broader focus on women's health may provide a favorable environment for Dare Bioscience's product development and commercialization efforts.

Comparison to Industry Standards

• Dare Bioscience's focus on first-in-category products aligns with the industry trend of developing innovative therapies to address unmet medical needs.
• The company's progress with XACIATO, Ovaprene, and Sildenafil Cream positions it as a potential leader in the women's health space, similar to companies like Myovant Sciences (now part of Sumitomo Pharma) which focused on women's health before being acquired.
• The development of non-hormonal contraceptive options like Ovaprene addresses a significant market need, comparable to the efforts of companies like Agile Therapeutics in the contraceptive space.
• The company's approach to female sexual arousal disorder with Sildenafil Cream is similar to the approach of companies like Palatin Technologies, which have also explored treatments in this area.
• The financial results, with a net loss of $30.1 million, are not unusual for a clinical-stage biotech company, but the company's cash position of $10.5 million will need to be monitored closely, similar to other companies in the sector.

Stakeholder Impact

• Shareholders will be interested in the progress of clinical trials and the commercial success of XACIATO.
• Employees will be impacted by the company's financial performance and strategic direction.
• Customers (patients) will benefit from the availability of new treatment options.
• Suppliers and collaborators will be impacted by the company's development and commercialization activities.
• Creditors will be interested in the company's financial stability and ability to repay debts.

Next Steps

• Dare Bioscience will continue to recruit for the Ovaprene Phase 3 study.
• The company will await additional FDA feedback on the Phase 3 design for Sildenafil Cream, expected in the second quarter of 2024.
• Dare Bioscience will provide quarterly revenue and launch updates for XACIATO throughout 2024.
• The company will evaluate next steps in the development program for DARE-PDM1.
• Dare Bioscience will begin planning for a Phase 2 clinical study of DARE-VVA1.
• The company will continue to evaluate a wide range of financing opportunities.

Key Dates

Keywords

womens health, biopharmaceutical, XACIATO, Ovaprene, Sildenafil Cream, bacterial vaginosis, contraceptive, female sexual arousal disorder, clinical trials, FDA, milestone payments, financial results